Tumor-associated antigens presented by alpha-type-1 polarized dendritic cells (TAA-αDC1) (TAA-αDC1)

Tumor-associated antigens (TAAs) presented by alpha-type-1 polarized dendritic cells (αDC1) refers to a therapeutic modality rather than a single molecular target or receptor. αDC1 cells are a specialized subset of dendritic cells matured with a specific cytokine cocktail—typically including IFN-α, IFN-γ, TNF-α, IL-1β, and poly-I:C—to maximize their production of IL-12p70 and their ability to prime Type-1 immune responses [1][2]. These cells are loaded with TAAs, which are proteins or peptides overexpressed by tumor cells, and then used as a vaccine to induce potent, antigen-specific cytotoxic T lymphocyte (CTL) responses [3]. The mechanism involves the processing and presentation of these antigens on MHC class I and II molecules, coupled with strong co-stimulatory signals that drive Th1 polarization and CD8+ T cell activation [4]. While the TAAs are the ultimate targets of the resulting immune response, the αDC1 cell acts as the delivery vehicle and immune adjuvant. This approach is currently being investigated in various clinical trials for cancers such as melanoma and glioma to overcome tumor-induced immunosuppression [5].

Other names

αDC1-presented tumor antigensAlpha-type-1 polarized dendritic cell-based vaccinesTAA-loaded αDC1Type-1 polarized DC-presented antigens

Alpha-type-1 polarized dendritic cells (αDC1) are loaded with tumor-associated antigens (TAAs), which they process and present via MHC class I and II molecules. These specialized dendritic cells produce high levels of IL-12p70, which is critical for the induction of Th1-type immunity and the priming of high-affinity, tumor-specific cytotoxic T lymphocytes (CTLs) that can infiltrate the tumor microenvironment and eliminate malignant cells [1][2].